Palantir Q4: Sell Now To Avoid Pain Later (Rating Downgrade)
Palantir’s Q4 revealed a 45% operating margin and 36% revenue growth, but its shares reflect over five years’ growth already.
infectiousdiseaseadvisor.com2d
Journavx, a Nonopioid Oral Pain Medication, Gets FDA Approval
The Food and Drug Administration has approved Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults.
ndtvprofit1d
Swiggy Q3 Review: Quick Commerce Remains Pain Point As Competition Intensifies
UBS maintained a 'Buy' rating on Swiggy stock with a target price of Rs 510, while Macquarie maintained an 'Underperform' ...
BioSpace6d
FDA Approves Vertex’s Journavx as First New Pain Drug in Decades
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
Algiax Announces Positive Data from Phase 2a Proof of Concept Study Evaluating AP-325 in Patients with Neuropathic Pain
Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced compelling topline data from its Phase 2a clinical ...
Weak demand weighs on Asian Paints Q3; analysts see more pain in near-term
Asian Paints' consolidated net profit attributable to the owners of the company declined 23.3 per cent year-on-year (Y-o-Y) ...
Buy Rating for Vertex Pharmaceuticals: FDA Approval of Journavx Boosts Market Potential and Stock Price Target
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...
Ranking the five best and worst stadiums in the NFL based on their Yelp reviews
NFL stadiums are meant to enhance fan experience, but some are much better at it than others. Here are the five best and worst NFL stadiums per Yelp.
Vistagen secures patent for non-opioid pain treatment
SOUTH SAN FRANCISCO, Calif. - Vistagen Therapeutics (VTGN), a clinical-stage biopharmaceutical company with a market ...
The plague of souring small loans is back
The microfinance sector is experiencing significant stress, with rising delinquencies affecting banks and non-bank lenders. Seasonal factors and increased borrower indebtedness have prompted cautious ...
China Universal Asset Management Co. Ltd. Grows Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
China Universal Asset Management Co. Ltd. boosted its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) ...
Canaccord maintains Buy rating, $101 target on Globus Medical stock
Canaccord Genuity maintained a Buy rating with a $101.00 price target for Globus Medical (NYSE:GMED) shares, which currently trades at $88.54. The firm's analysis supports the company's ongoing ...